04.02.2010 11:35:00
|
Phase Forward to Speak at Key Industry Events in February
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate in two industry events this month: The 13th Annual DIA Workshop in Japan for Clinical Data Management (Booths 4 and 5) and VIB Pharma’s 11th Annual Clinical Trial Supply (Booth 3).
At DIA’s Workshop in Japan for Clinical Data Management, February 4-5 in Tokyo, three Phase Forward representatives will participate in key sessions including:
Who: |
Andy Brock, International Services Development Director, Phase Forward | ||||
What: |
"New Approaches for CDM Infrastructure – Halfway up Mount Fuji: Japan Re-emerges as a Force in the Asia-Pacific Drug Development Market” | ||||
When: |
Friday, February 5, 9:00-10:30 a.m. JST | ||||
Who: |
Aubrey Blazey, Architecture Consultant, Phase Forward | ||||
What: |
"CDISC Reality: Simplifying Trial Data Extraction with CDISC ODM as a Web Service Interface” | ||||
When: |
Friday, February 5, 11:00 a.m.-12:00 p.m. JST | ||||
Who: |
Ralph Johnson, Clinical Design Consultant, Phase Forward | ||||
What: |
"CDISC Reality: Building an eCRF CDASH Library – A Case Study” | ||||
When: |
Friday, February 5, 11:00 a.m.-12:00 p.m. JST |
Later in the month at VIB Pharma’s 11th Annual Clinical Trial Supply, February 23-24 in London, Phase Forward will exhibit its Interactive Response Technology solution and lead the following session:
Who: |
Johan Verboven, Manager of IRT Project Management, Phase Forward | ||||
What: |
"Cradle to Grave Tracking of Investigational Products – Pre-planning for Drug Reconciliation” | ||||
When: |
Wednesday, February 24, 11:45 a.m.-12:15 p.m. GMT |
Members of the media interested in speaking with Phase Forward should contact Maria Sumner at +44 1628 640743 or maria.sumner@phaseforward.com or Juli Greenwood at 781-672-3137 or jgreenwood@chenpr.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Oracle Corp.mehr Nachrichten
31.12.24 |
NASDAQ Composite Index-Wert Oracle-Aktie: So viel Gewinn hätte eine Investition in Oracle von vor 5 Jahren abgeworfen (finanzen.at) | |
24.12.24 |
NASDAQ Composite Index-Wert Oracle-Aktie: So viel hätte eine Investition in Oracle von vor 3 Jahren abgeworfen (finanzen.at) | |
17.12.24 |
NASDAQ Composite Index-Wert Oracle-Aktie: So viel Gewinn hätte ein Investment in Oracle von vor einem Jahr eingefahren (finanzen.at) | |
10.12.24 |
Schwacher Handel in New York: NASDAQ Composite gibt zum Ende des Dienstagshandels nach (finanzen.at) | |
10.12.24 |
Anleger in New York halten sich zurück: S&P 500 sackt schlussendlich ab (finanzen.at) | |
10.12.24 |
MÄRKTE USA/Etwas leichter vor US-Daten - Oracle sehr schwach (Dow Jones) | |
10.12.24 |
Oracle-Aktie dennoch klar im Minus: Hohe KI-Nachfrage bringt Oracle auf Erfolgskurs (dpa-AFX) | |
10.12.24 |
Schwacher Handel: Das macht der S&P 500 am Nachmittag (finanzen.at) |
Analysen zu Oracle Corp.mehr Analysen
03.01.25 | Oracle Sector Perform | RBC Capital Markets | |
10.12.24 | Oracle Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
10.12.24 | Oracle Sector Perform | RBC Capital Markets | |
10.12.24 | Oracle Neutral | JP Morgan Chase & Co. | |
10.12.24 | Oracle Buy | UBS AG |
Aktien in diesem Artikel
Oracle Corp. | 156,80 | -1,68% |
Indizes in diesem Artikel
NASDAQ Comp. | 19 631,55 | -1,18% |